Breath test could uncover hidden asthma inflammation in routine doctor visits
NCT ID NCT07675044
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study uses a quick, non-invasive breath test (FeNO) to measure airway inflammation in adults with asthma who are treated in primary care or community specialty clinics. The goal is to see how many patients have type 2 inflammation, which often goes undetected. Researchers hope the findings will help improve referral pathways to asthma specialists.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FeNO Breath Test
- What this could lead to
- If successful, this could help primary care doctors better identify asthma patients with type 2 inflammation and refer them to specialists more effectively.
- What could go wrong
- This is an observational study, not a treatment trial. It measures inflammation but does not test a new therapy, so direct patient benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mount Sinai Health System
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?